Clinical and Immunologic Profiles in Incomplete Lupus Erythematosus and Improvement with Hydroxychloroquine Treatment.
Clinical and Immunologic Profiles in Incomplete Lupus Erythematosus and Improvement with Hydroxychloroquine Treatment.
复制标题
DOI：
10.1155/2016/8791629
复制
发表时间：
2016
影响因子：
4
通讯作者：
Liao D
中科院分区：
文献类型：
--
作者：
Olsen NJ;McAloose C;Carter J;Han BK;Raman I;Li QZ;Liao D
Objective.本研究的目的是评估SLE分类标准的性能，定义不完全性红斑狼疮（ILE）患者，并探讨这些患者的特征，这些特征可能是有用的疾病状态和羟氯喹反应的指标。方法.根据1997年美国风湿病学会标准定义的ILE（N = 70）和SLE（N = 32）患者使用2012年系统性狼疮国际合作临床标准重新分类。疾病活动，病人报告的结果，和I型干扰素（IFN-）诱导基因，自身抗体和细胞因子的水平进行了测量。将接受羟氯喹（HCQ）治疗的亚组与未接受该药物治疗的患者进行比较。结果分类集相关（R2 = 0.87）。ILE患者较SLE患者年龄大（P = 0.0043），疾病活动性评分低（P < 0.001），对健康状况的不满意程度高（P = 0.034）。ILE与较低水平的巨噬细胞源性细胞因子和表达的I型IFN诱导基因水平相关。与未接受HCQ治疗的ILE患者相比，HCQ治疗的ILE患者自我报告的健康状况评分更好，I型IFN诱导基因的表达水平更低。结论2012 SLICC SLE分类标准将有助于在试验中定义ILE。ILE患者在接受HCQ治疗时具有更好的健康状况和免疫特征。
Objective. The study goals were to evaluate performance of SLE classification criteria, to define patients with incomplete lupus erythematosus (ILE), and to probe for features in these patients that might be useful as indicators of disease status and hydroxychloroquine response. Methods. Patients with ILE (N = 70) and SLE (N = 32) defined by the 1997 American College of Rheumatology criteria were reclassified using the 2012 Systemic Lupus International Collaborating Clinics criteria. Disease activity, patient reported outcomes, and levels of Type I interferon- (IFN-) inducible genes, autoantibodies, and cytokines were measured. Subgroups treated with hydroxychloroquine (HCQ) were compared to patients not on this drug. Results. The classification sets were correlated (R2 = 0.87). ILE patients were older (P = 0.0043) with lower disease activity scores (P < 0.001) and greater dissatisfaction with health status (P = 0.034) than SLE patients. ILE was associated with lower levels of macrophage-derived cytokines and levels of expressed Type I IFN-inducible genes. Treatment of ILE with HCQ was associated with better self-reported health status scores and lower expression levels of Type I IFN-inducible genes than ILE patients not on HCQ. Conclusion. The 2012 SLICC SLE classification criteria will be useful to define ILE in trials. Patients with ILE have better health status and immune profiles when treated with HCQ.